News & Updates
Showing Multidisciplinary articles
Showing

Long-term ACS outcomes similar between TiNO-coated and everolimus-eluting stents
Neither titanium-nitride-oxide (TiNO)–coated stents nor third-generation everolimus-eluting stents (EES) are necessarily better than the other in the treatment of patients with acute coronary syndromes (ACS), with a study showing no significant difference in long-term outcomes following placement of TiNO-coated stents or EES.

Vitamin D supplementation flops for TB prevention in children
A 3-year course of weekly oral vitamin D supplementation, while safe and effective at increasing serum 25(OH)D concentrations, does little to reduce the risk of contracting tuberculosis (TB) infection in children, as shown in the results of a phase III study.

Brepocitinib doses hold promise in treatment of psoriatic arthritis
Treatment with brepocitinib at 30 and 60 mg daily outperforms placebo at relieving signs and symptoms of psoriatic arthritis (PsA), with a safety profile consistent with that seen in other brepocitinib trials, according to data from a phase IIb study.

Which COVID-19 vaccine should SARDs patients on immunomodulators use?
Vaccination with either BNT162b2 or mRNA-1273 results in a comparable risk of breakthrough COVID-19 infection among patients with systemic autoimmune rheumatic diseases (SARDs) using immunomodulatory medication, a study has shown.

COVID vax fortifies defences against emerging omicron variants in previously infected youths
For children and adolescents who have been previously exposed to SARS-CoV-2 infection, vaccination with BNT162b2 appears to provide additional protection against omicron BA.4 or BA.5 and XBB variant infections, according to a study from Singapore.

12-year review of HK Breast Cancer Registry: Neoadjuvant chemo effective in stage ≥II, HER2-positive and triple-negative disease
A 12-year review of Hong Kong Breast Cancer Registry (HKBCR) records of patients diagnosed with breast cancer in 2006–2017 showed that neoadjuvant chemotherapy (NAC) was effective in tumour downstaging, with one-fifth of patients subsequently achieving pathological complete response (pCR) in the breast and axillary lymph nodes. Patients with HER2-positive (nonluminal) and triple-negative disease were most likely to achieve pCR.



